Characterisation of Expression the Arginine Pathway Enzymes in Childhood Brain Tumours to Determine Susceptibility to Therapeutic Arginine Depletion

Figure 3

Expression of arginine pathway enzymes in LGG expressed as a percentage normalised to 100% of the total number of cases scored per antibody. Tumours were classed as being deficient if the expression level of an individual pathway enzyme was 20% or lower. High expression was defined as >50% antibody staining (see supplementary table 2 for number of samples analysed per antibody in the LGG cohort).